Onesource Specialty Pharma Limited · NSE:ONESOURCE
Onesource Specialty Pharma — Q4 FY2025 Earnings Presentation
19 slides from Onesource Specialty Pharma's earnings presentation, May 5, 2025
Slide 1: OneSource Specialty Pharma Ltd - The New Way to CDMO
ONE SOUICE THE NEW WAY TO CDMO (oa) seen OneSource Specialty Pharma Ltd | May 5, 2025
Slide 2: Safe harbor
Safe harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 3: Strong all-round performance in first year delivering financial outlook
Strong all-round performance in first year delivering financial outlook on revenues and profitability Revenues (million) EBITDA (million) EBITDA Margins (%) PAT ( million) The %ages reflect YoY increase for the Q4’25 and FY25 50.4 ↑ 22% 21.6 ↑ 79% 42.8 ↑ 1362 bps 11.7 ↑ 100% + Q4’25 4,260 1,825 992
Slide 4: OneSource inception story playing out
OneSource inception story playing out We’re delighted to announce a 30% revenue increase, driven by all-round robust growth. EBITDA grew significantly due to product mix in favour of Drug Device Combinations (DDCs) and Biologics, and higher operational efficiencies. Our business has been driven by s
Slide 5: All time high quarterly performance with Q4'25 revenue at $50m
All time high quarterly performance with Q4'25 revenue at $50m and EBITDA margin of 42% In $ m Q4’244 Q4’25 Q3’25 YoY QoQ Key Updates Revenue 41.4 50.4 46.5 22% 9% ▷ Revenue: Q4'25 revenue at $ 50.4m / ₹4,260m registered a 22% growth YoY with contribution from all businesses EBITDA 12.1 21.6 16.8 79
Slide 6: Full year revenue up by 30%, EBITDA up 2x
Full year revenue up by 30%, EBITDA up 2x propelled by robust all-round growth In $ m FY244 FY25 YoY Key Updates Revenue 131.2 171.11 30% ▷ Revenue: FY25 revenue at $171.1m / ₹14,449m registered a EBITDA 27.1 55.21 104% 30% growth YOY driven by 16 new DDC project MSAs, initiation of CDMO offering fo
Slide 7: Strong financial indicators demonstrate continued upward trajectory
Strong financial indicators demonstrate continued upward trajectory of growth, and profitability Revenues ($m) EBITDA1 ($m) and Margins (%) PAT2 ($m) 46.5 50.4 25 43% 50% 11.7 41.4 39.6 36% 20 40% 34.6 29% 15 22% 23% 30% 3.8 10 20% 5 10% -0.1 -4.3 12.1 7.6 9.2 16.8 21.6 -1.3 0 0% Q4'24 Q1'25 Q2'25 Q
Slide 8: Adding new customers, winning more business from existing customers
Adding new customers, winning more business from existing customers, maintaining stellar compliance record 39 21 New RFPs/ licensing deals won RFP/ licensing deals won from New Customers Cumulative for OneSource 15 70+ New Additions in FY25 New customers Total customers 6 9 NBEs (1) and NCE-1s (5) p
Slide 9: Business Outlook and Growth Strategy
Business Outlook and Growth Strategy Q4’25 & FY25
Slide 10: Investing $100 million in capital expenditures to service partner demand
Investing $100 million in capital expenditures to service partner demand and drive growth across our modalities ▷ $100 million capex planned for capacity expansion Capacity Current Planned Target Completion ▷ Multiple lines being added (particularly DDCs), with Cartridges (in millions) ~40 ~220 Phas
Slide 11: Reaffirming outlook for FY25-28 revenue CAGR of >30%
Reaffirming outlook for FY25-28 revenue CAGR of >30% with EBITDA margins of ~ 40% In $ m FY23A2,3 FY24A,2,3 FY25A ▷ OneSource reaffirms its post–listing revenue growth guidance FY 23-25 CAGR of >30% (FY25-28) with a steady-state EBITDA margins of Revenue 85 131 1711 42% ~40% led by DDCs, injectables
Slide 12: Earnings call schedule, speakers and dial in
Day: Tuesday Schedule: Date: 6th May 2025 Time: 9:00 AM IST Arun Kumar, Founder & Non-Executive Chairperson Speakers: Neeraj Sharma, CEO & MD Anurag Bhagania, CFO +91 22 6746 8181 Dial In: +91 22 7115 8193 Diamond Pass: Click here for early registration
Slide 13: about.
about. NEeSOurce TT .
Slide 14: Scaling a first-of-its-kind CDMO platform
Scaling a first-of-its-kind CDMO platform, distinguished by extensive capabilities and robust financial metrics ONE OF ITS KIND CDMO ROBUST MANUFACTURING & PRESENCE ACROSS HIGHLY ATTRACTIVE STRONG AND DEDICATED PLATFORM COMPLIANCE TRACK RECORD MODALITIES INCLUDING GLP-1 FINANCIAL PROFILE MANAGEMENT
Slide 15: One of the widest offerings with industry leading installed capacities
One of the widest offerings with industry leading installed capacities and stellar compliance record Drug-device combinations Multi-modal Biologics Soft gelatin capsules1 Sterile Injectables Penicillin fill-finish Integrated Biologics and drug products site development centre Area 450,000 70,000 42,
Slide 16: OneSource stands out among global CDMOs
OneSource stands out among global CDMOs by offering a diverse, multi-modality approach with a comprehensive suite of services Drug-device Combinations Biologics Soft gelatin Sterile fill-finish (excluding including GLP-1s (DS and DP) capsules1 DDCs) CDMO Market 38 Size ($bn) 20 18 12 12 10 13 5 2023
Slide 17: Strong leadership team with global industry expertise
Strong leadership team with global industry expertise and delivery track record… Neeraj Sharma, CEO and MD Biju Matthews, Chief Operating Officer • 30+ years of global experience in pharma • 30+ years of pharma experience; Responsible for building the state-of-the-art drug product and drug substance
Slide 18: Supported by a diverse and independent Board
…supported by a diverse and independent Board to build on the group’s strong corporate governance legacy Arun Kumar Debarati Sen Arun Kumar is a first-generation entrepreneur and known for his ability to identify great opportunities in Debarati is a proven global business leader known for driving tr
Slide 19: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd investors@onesourcecdmo.com investors@onesourcecdmo.com Registered Office: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India T: +91 22 2789 2924 F: +91 22 2789 2942 Corporate Office: O
OneSource Specialty Pharma — Q4 FY2025 Earnings Presentation on 6ix